ELVN Latest Report

Performance Review

Enliven (stock code: ELVN) recorded an operating revenue of -26896000 yuan at the end of 2024, down from -22729000 yuan at the end of 2023. Despite the negative revenue, it reflects the significant financial pressure and challenges faced in its business activities.

Key Financial Data

1. The operating revenue in 2024 was -26896000 yuan, down about 18.38% from 2023.

2. Marketing, sales, and general management expenses increased to 6172000 yuan, indicating insufficient management efficiency.

3. Research and development expenses increased to 20724000 yuan, causing short-term financial pressure but may support long-term competitiveness.

Peer Comparison

1. Industry-wide analysis: If other peer companies also see a decline in revenue, it may reflect the overall weakness of the industry. If the industry performs well while the company declines, it indicates the company's insufficient competitiveness in the market.

2. Peer evaluation analysis: Compared to peers, Enliven's revenue performance is weaker, especially in the context of industry recovery, negative growth indicates a decline in market share or weakened brand influence.

Summary

Enliven's revenue decline in 2024 is mainly affected by changes in the market environment, intensified competition, and insufficient internal management efficiency. Although the company has increased its R&D investment, the short-term financial pressure has also increased, making its overall competitiveness fragile.

Opportunities

1. Through continuous R&D investment, developing high-value-added products to meet market demand, it may achieve revenue recovery in the future.

2. The transformation of market demand to health consumption and service consumption provides new growth opportunities for the company.

3. Strengthening management efficiency and sales strategies, optimizing cost control, helps to enhance the company's profitability.

Risks

1. Macroeconomic fluctuations may further affect market demand, leading to continuous revenue decline.

2. Intense competition may result in further reduction of product gross margin, affecting the company's profitability.

3. Although R&D investment is beneficial for competitiveness enhancement in the long run, it may cause increased liquidity pressure in the short term, affecting operations.